Norepinephrine transporter inhibitors and their therapeutic potential

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The norepinephrine transporter (NET) is located in the plasma membrane of noradrenergic neurons, where it functions to take up synaptically released norepinephrine (NE). The NET thus serves as the primary mechanism for the inactivation of noradrenergic signaling. Some potent and selective or mixed NET inhibitors (e.g., reboxetine and atomoxetine) have been successfully developed to treat a variety of mental disorders such as depression and attention deficit hyperactivity disorder (ADHD). However, to date, only a very limited number of NET-selective inhibitors are available. New potent and selective NET inhibitors may find application in the treatment of mental disorders or in PET imaging, and may enhance our basic understanding of these illnesses. In the present review, both previously reported and newly designed NET inhibitors, as well as their therapeutic and imaging potential, will be discussed. Two types of molecules, the conformationally constrained tropanes and the piperidine-based nocaine/modafinil hybrid ligands, represent new leads and provide good opportunities for discovering novel potent and selective NET inhibitors that are useful as therapies and imaging agents for the NET.

Original languageEnglish (US)
Pages (from-to)1235-1244
Number of pages10
JournalDrugs of the Future
Volume29
Issue number12
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Therapeutics
Mental Disorders
Tropanes
Adrenergic Neurons
Attention Deficit Disorder with Hyperactivity
Norepinephrine
Cell Membrane
Depression
Ligands

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Norepinephrine transporter inhibitors and their therapeutic potential. / Zhou, Jia.

In: Drugs of the Future, Vol. 29, No. 12, 12.2004, p. 1235-1244.

Research output: Contribution to journalArticle

@article{7879a37cf86d45e2a03808d5047c3ede,
title = "Norepinephrine transporter inhibitors and their therapeutic potential",
abstract = "The norepinephrine transporter (NET) is located in the plasma membrane of noradrenergic neurons, where it functions to take up synaptically released norepinephrine (NE). The NET thus serves as the primary mechanism for the inactivation of noradrenergic signaling. Some potent and selective or mixed NET inhibitors (e.g., reboxetine and atomoxetine) have been successfully developed to treat a variety of mental disorders such as depression and attention deficit hyperactivity disorder (ADHD). However, to date, only a very limited number of NET-selective inhibitors are available. New potent and selective NET inhibitors may find application in the treatment of mental disorders or in PET imaging, and may enhance our basic understanding of these illnesses. In the present review, both previously reported and newly designed NET inhibitors, as well as their therapeutic and imaging potential, will be discussed. Two types of molecules, the conformationally constrained tropanes and the piperidine-based nocaine/modafinil hybrid ligands, represent new leads and provide good opportunities for discovering novel potent and selective NET inhibitors that are useful as therapies and imaging agents for the NET.",
author = "Jia Zhou",
year = "2004",
month = "12",
doi = "10.1358/dof.2004.029.12.855246",
language = "English (US)",
volume = "29",
pages = "1235--1244",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Norepinephrine transporter inhibitors and their therapeutic potential

AU - Zhou, Jia

PY - 2004/12

Y1 - 2004/12

N2 - The norepinephrine transporter (NET) is located in the plasma membrane of noradrenergic neurons, where it functions to take up synaptically released norepinephrine (NE). The NET thus serves as the primary mechanism for the inactivation of noradrenergic signaling. Some potent and selective or mixed NET inhibitors (e.g., reboxetine and atomoxetine) have been successfully developed to treat a variety of mental disorders such as depression and attention deficit hyperactivity disorder (ADHD). However, to date, only a very limited number of NET-selective inhibitors are available. New potent and selective NET inhibitors may find application in the treatment of mental disorders or in PET imaging, and may enhance our basic understanding of these illnesses. In the present review, both previously reported and newly designed NET inhibitors, as well as their therapeutic and imaging potential, will be discussed. Two types of molecules, the conformationally constrained tropanes and the piperidine-based nocaine/modafinil hybrid ligands, represent new leads and provide good opportunities for discovering novel potent and selective NET inhibitors that are useful as therapies and imaging agents for the NET.

AB - The norepinephrine transporter (NET) is located in the plasma membrane of noradrenergic neurons, where it functions to take up synaptically released norepinephrine (NE). The NET thus serves as the primary mechanism for the inactivation of noradrenergic signaling. Some potent and selective or mixed NET inhibitors (e.g., reboxetine and atomoxetine) have been successfully developed to treat a variety of mental disorders such as depression and attention deficit hyperactivity disorder (ADHD). However, to date, only a very limited number of NET-selective inhibitors are available. New potent and selective NET inhibitors may find application in the treatment of mental disorders or in PET imaging, and may enhance our basic understanding of these illnesses. In the present review, both previously reported and newly designed NET inhibitors, as well as their therapeutic and imaging potential, will be discussed. Two types of molecules, the conformationally constrained tropanes and the piperidine-based nocaine/modafinil hybrid ligands, represent new leads and provide good opportunities for discovering novel potent and selective NET inhibitors that are useful as therapies and imaging agents for the NET.

UR - http://www.scopus.com/inward/record.url?scp=13544263446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544263446&partnerID=8YFLogxK

U2 - 10.1358/dof.2004.029.12.855246

DO - 10.1358/dof.2004.029.12.855246

M3 - Article

VL - 29

SP - 1235

EP - 1244

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 12

ER -